POINT: Point Biopharma Holders Resisting Eli Lilly Tender Offer

(marketscreener.com) By Colin Kellaher Eli Lilly's planned $1.4 billion acquisition of Point Biopharma Global has hit a speed bump, as the radiopharmaceutical company's shareholders appear to not be going along with the tender offer. Eli Lilly on Friday said it has extended its $12.50-a-share cash tender offer for Point until Dec. 1 to give the companies...https://www.marketscreener.com/quote/stock/ELI-LILLY-AND-COMPANY-13401/news/Point-Biopharma-Holders-Resisting-Eli-Lilly-Tender-Offer-45385370/?utm_medium=RSS&utm_content=20231117